BLD-2660
(COVID-19 Lung Disease and IPF)
Phase 2a (2Q20)
Revolutionizing the Treatment of Fibrotic Disease.
Revolutionizing the Treatment of Fibrotic Disease.
Revolutionizing the Treatment of Fibrotic Disease.
Pipeline
We are positioned to build a pipeline across a range of fibrotic diseases.
BLD-0409
(NASH)
Phase 1
BLD-2184
(Neurodegeneration)
Preclinical
Join our team
We are looking for people with the passion and commitment of the values we live by.
Passion and commitment to our mission
Accountability to the team
Integrity in everything we do
Be fearless
Recent News
November 26, 2019
Blade Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference​
November 14, 2019
Blade Therapeutics to Present at the Stifel 2019 Healthcare Conference
COVID-19 Response
In response to the ongoing pandemic, we are evaluating the role of host and SARS-CoV cysteine proteases in viral replication, exacerbation of acute pneumonia, and post-recovery lung dysfunction. In April 2020 we initiated a controlled trial of BLD-2660, a Phase 2 ready oral small molecule, to treat COVID-19-related lung disease in hospitalized patients (Clinicaltrials.gov NCT04334460).
Bringing life changing and revolutionary treatments to patients with fibrotic diseases.